Brainstorm Cell Therapeutics (NASDAQ: BCLI) reported Q2 EPS of ($0.36), $0.16 worse than the analyst estimate of ($0.20).

"We continue to take important steps to advance NurOwn in ALS and progressive MS and position ourselves for sustained success," said Chaim Lebovits, Chief Executive Officer of BrainStorm. "Our discussions with leading ALS experts have provided invaluable insights that we will leverage as we assess NurOwn\'s potential regulatory pathways in major markets. We also doubled our capacity to supply NurOwn® across Israel and Europe, supporting our readiness to provide broad patient access following any potential approval. Looking ahead, we will continue to work expeditiously with key opinion leaders and the broader ALS community to address the urgent unmet needs of ALS patients, who remain our greatest inspiration."

For earnings history and earnings-related data on Brainstorm Cell Therapeutics (BCLI) click here.